CClinicalTrials.gg
Status unknownNCT04029207Updated Jan 29, 2020

The ASOS-2 Trial Maternal Mortality Sub-study

An observational study in Maternal Mortality, Cesarean Section and Africa, sponsored by University of Cape Town. Status unknown at 1 site in South Africa. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-01-29.

Sponsored by University of Cape Town · Observational

The sponsor has not verified this record recently (last verified Jan 2020), so the status shown — last known as Enrolling by invitation — may be out of date.
Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
100
Ages
18 Years and older
Sex
Female
01

Study summary

This sub-study is a mixed-methods analysis of a prospective case-series of maternal deaths within the African Surgical OutcomeS-2 trial cohort. The aims of the sub-study are i) to describe the contextual factors that contribute towards maternal deaths after caesarean delivery in Africa using a conceptual framework of "transport-treatment-training" and ii) to classify the maternal deaths in the ASOS-2 trial according to the WHO ICD-10 maternal mortality reporting standard. Data will be extracted from the ASOS-2 trial database. A sub-study case report form (CRF) and semi-structured telephonic interviews will be used to gather additional information from clinicians who were experienced a maternal death during the trial.

Read the detailed description

This sub-study is a mixed-methods analysis of a prospective case-series of maternal deaths within the African Surgical OutcomeS-2 trial cohort. The aims of the sub-study are i) to describe the contextual factors that contribute towards maternal deaths after caesarean delivery in Africa using a conceptual framework of "transport-treatment-training" and ii) to classify the maternal deaths in the ASOS-2 trial according to the WHO ICD-10 maternal mortality reporting standard. Data will be extracted from the ASOS-2 trial database. When a maternal death is captured on the trial database, the data manager will flag the event. The hospital that registered the death will be contacted and invited to take part in the sub-study. A sub-study case report form (CRF) and semi-structured telephonic interviews will be used to gather additional information from clinicians who were experienced a maternal death during the trial.

This study uses 2 a priori frameworks for describing maternal deaths:

i) The "transport-treatment-training" framework developed by Dr Andrew Shennan (personal communication). This framework suggests that the important determinants (modifiable contextual factors) of maternal mortality can be classified as being related to transport, treatment and training factors.

  • Transport refers to the manner in which the patient accesses existing care. This includes decision to seek help, modes of transportation to the hospital, and inter-facility transportation. We consider the healthcare access network in this category.
  • Treatment refers to the manner in which the case was managed at the healthcare facility. It includes delays in diagnosis and decision making as well as delays between decision making and physical intervention (e.g. time from decision for caesarean delivery to time of delivery of the infant). Treatment also includes appropriateness of treatment decisions and the availability of resources needed to provide recommended treatment.
  • Training refers to the availability of skilled health care providers and the need for training / upskilling of existing health care providers.

ii) The WHO application of ICD-10 codes to deaths during pregnancy, childbirth and puerperium (ICD MM) classification. Within this framework, deaths are described as having a final direct cause, an underlying cause that leads to the final cause, and contributory causes that did not directly cause death, but worsened physiological status or accelerated the underlying event.

The underlying cause of death is defined as the disease or condition that initiated the morbid chain of events leading to death or the circumstances of the accident or violence that produced a fatal injury. Underlying causes will be specified in as much detail as available. The underlying cause will be classified into one of 8 categories:

  1. Hypertensive disorders in pregnancy
  2. Obstetric haemorrhage
  3. Pregnancy-related infection
  4. Other obstetric complications
  5. Unanticipated complications of management (iatrogenic)
  6. Non-obstetric complications (non-obstetric disease, e.g. cardiac disease, malaria)
  7. Unknown / Undetermined
  8. Coincidental external causes (e.g. interpersonal violence)
02

Conditions studied

  • Maternal Mortality
  • Cesarean Section
  • Africa

Browse trials for

03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

African mothers who die during or after caesarean delivery. The primary study is a cluster randomised trial which samples hospitals across Africa purposively.

Inclusion criteria

  • adult patients
  • aged 18 years and over,
  • admitted to participating hospitals
  • undergoing elective and non-elective caesarean delivery
  • who die following their operation before leaving hospital and within 30 days after the operation.

Exclusion criteria

Exclusion Criteria:

  • prior participation in ASOS-2
  • caesarean delivery at a hospital other than the study hospital (left censored)
  • patients who are transferred to another hospital before death (right censored)
04

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • African Surgical OutcomeS-2 Trial

    The ASOS-2 Trial is a cluster randomised trial purposively recruiting hospitals across Africa. To be eligible for inclusion a hospital must perform at least 20 cases of adult in-patient surgery with anaesthesia per week, have local ethics approval for the trial, have local hospital management approval and have established a local hospital study team. The trial excludes hospitals with lower surgical volume. The trial aims to include all consecutive adult in-patient surgical cases at participating hospitals (both elective and emergency surgery). Patients under the age of 18 and patients who have already been recruited into the trial are excluded from recruitment. Follow-up is in-hospital, censored at 30 days.

    Procedure: Cesarean section

Interventions

  • ProcedureCesarean section

    Abdominal, operative delivery of the fetus

05

What researchers measure

Primary outcomes

  1. Transport: Mode of transport

    Nominal: walking, private transport, ambulance, public transport

    Time frame: On the day of hospital admission

  2. Transport: Distance

    Continuous: distance in kilometers from patient's home to hospital

    Time frame: On the day of hospital admission

  3. Transport: Time

    Continuous: time in hours from patient's home to hospital

    Time frame: On the day of hospital admission

  4. Transport: Delay in seeking healthcare

    Binary: Obstetrician opinion whether there was a clinically important delay in seeking care

    Time frame: On the day of hospital admission

  5. Transport: Delay in transport to healthcare

    Binary: Obstetrician opinion whether there was a clinically important delay in transport

    Time frame: On the day of hospital admission

  6. Transport: Inter-facility delay

    Binary: Did the patient die while waiting for inter-facility transfer?

    Time frame: At time of death (death recorded in-hospital, censored at 30 days)

  7. Treatment: Referral to high level of care

    Binary: Whether or not referral to higher level of care took place

    Time frame: In-hospital censored at 30 days

  8. Treatment: Prophylactic uterotonic use

    Nominal: Oxytocin, Ergometrine, Misoprostil, Carbetocin, None

    Time frame: On day of caesarean section, at time of caesarean section

  9. Treatment: Therapeutic uterotonic use

    Nominal: Oxytocin, Ergometrine, Misoprostil, Carbetocin, None

    Time frame: On day of caesarean section, at time of caesarean section

  10. Treatment: Surgical safety checklist

    Binary: Whether or not a surgical safety checklist was used

    Time frame: On day of caesarean section, at time of caesarean section

  11. Treatment: Type of anaesthetic

    Nominal: Regional, general with endotracheal intubation, general without endotracheal intubation.

    Time frame: On day of caesarean section, at time of caesarean section

  12. Treatment: Airway aspiration

    Binary: Whether or not airway aspiration occurred

    Time frame: On day of caesarean section, at time of caesarean section

  13. Treatment: Desaturation

    Binary: Whether or not desaturation below 90% occurred during management of the airway

    Time frame: On day of caesarean section, at time of caesarean section

  14. Treatment: Spinal hypotension

    Binary: Whether or not spinal hypotension occured; systolic BP \<= 90mmHg

    Time frame: On day of caesarean section, at time of caesarean section

  15. Treatment: Interventions to arrest bleeding

    Nominal: Which techniques were used? over-sowing, uterine compression suture, uterine artery ligation, uterine tourniquet, intrauterine balloon, hysterectomy, uterine artery embolisation

    Time frame: In hospital, censored at 30 days

  16. Treatment: Blood products

    Nominal: Which products were given? Red blood cells, fresh frozen plasma, freeze dried plasma, cryoprecipitate, platelets, whole blood.

    Time frame: In hospital, censored at 30 days

  17. Treatment: Availability of medications

    Nominal: Oxygen, Propofol, Thiopentone, Etomidate, Ketamine, Suxamethonium, Rocuronium, Nitrous Oxide, Halothane, Isoflurane, Sevoflurane, Oxytocin, Ergometrine, Syntometrine, Misoprostil, Prostaglandin F2alpha, Carbetocin, Phenylephrine, Ephedrine, Adrenalin, Noradrenalin, Morphine, Fentanyl, Pethidine, Lignocaine, Bupivacaine, Tranexamic Acid

    Time frame: On day of caesarean section

  18. Treatment: Availability of blood products

    Nominal: Red blood cells, Plasma, Platelets, Cryoprecipitate

    Time frame: On day of caesarean section

  19. Treatment: Availability of resuscitation equipment

    Nominal: Airway suction, endotracheal intubation equipment, mechanical ventilator, supraglottic airway devices, defibrillator,

    Time frame: On day of caesarean section

  20. Treatment: Availability of monitoring equipment

    Nominal: Which monitoring equipment are available in the recovery area and the postoperative ward? O2 saturation, blood pressure, heart rate monitor, thermometer

    Time frame: On day of caesarean section

  21. Treatment: Recovery area

    Binary: Is there a dedicated area where the patient is monitored during recovery from anaesthesia for caesarean section?

    Time frame: On day of caesarean section

  22. Treatment: Provider-patient ratio

    Interval: Nurse-to-patient ratio in postoperative ward (during the day, during the night)

    Time frame: On day of caesarean section

  23. Treatment: Delay in diagnosis

    Binary: Obstetrician opinion whether a clinical important delay in diagnosis occurred

    Time frame: On day of caesarean section

  24. Treatment: Delay between diagnosis and caesarean section

    Binary: Obstetrician opinion whether a clinical important delay between diagnosis and caesarean section occurred

    Time frame: On day of caesarean section

  25. Treatment: Access to hospital resources

    Nominal: Obstetrician opinion whether delayed access or lack of hospital resources contributed to the death: water supply, electricity, medications, telephone, anaesthetic equipment, surgical equipment, monitoring equipment, operating theatre, nursing or assistant, on-call senior obstetric doctor, on-call senior anaesthetic doctor, advice from referral center.

    Time frame: On day of caesarean section

  26. Training: Level of training

    Nominal: Provider level of training at caesarean seciton (for anaesthesia and surgery): Specialist, specialist trainee, non-specialist doctor, non-doctor

    Time frame: At time of caesarean section

Secondary outcomes

  1. Cause of death

    WHO ICD-10 maternal mortality reporting standard

    Time frame: Maternal death is recorded in-hospital, censored at 30 days.

06

Study locations

1 site
  • Groote Schuur Hospital
    Observatory, Western Cape 7925, South Africa
07

References and documents

Individual participant data

Plan to share: Undecided — The Principle Investigator will receive requests to share individual participant data and will decide on a case by case basis.

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT04029207
Lead sponsor
University of Cape Town
Collaborators
Bill and Melinda Gates Foundation
Responsible party
Bruce Biccard (Professor, University of Cape Town) — Principal investigator
First posted
Jul 23, 2019
Start date
May 6, 2019
Primary completion
Jul 31, 2020 (estimated)
Completion
Jul 31, 2020 (estimated)
Last update
Jan 29, 2020

Study contacts

Professor Bruce M Biccard
principal investigator · University of Cape Town

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion